Skip to main content
Midas Edge

Zenas BioPharma Inc

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

ZBIO$28.58+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

Consolidated Statements of Changes in Convertible Preferred Stock and

Stockholders’ Equity (Deficit)

(in thousands, except share data)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Convertible Preferred Stock · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Series Seed · ​ · Series A · ​ · Series B · ​ · Series C · ​ · Common Stock​ · ​ · Additional Paid-in · ​ · Accumulated Other Comprehensive · ​ · Accumulated · ​ · Total Stockholders' Equity
​ · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Income (Loss) · Deficit · (Deficit)
Balance as of December 31, 2022​1,785,714​$956​17,589,380​$55,840​77,052,632​$183,290​—$—​1,549,275​$—​$1,034​$(41)​$(193,279)​$(192,286)
Issuance of Series B convertible preferred stock as payment of Xencor milestone, net of issuance costs of $0​—​​—​—​​—​4,189,955​​10,000​—​—​—​​—​​—​​—​​—​​—
Exercises of common stock options​—​​—​—​​—​—​​—​—​—​27,579​​—​​116​​—​​—​​116
Stock-based compensation expense​—​​—​—​​—​—​​—​—​—​—​​—​​3,495​​—​​—​​3,495
Foreign currency translation adjustment​—​​—​—​​—​—​​—​—​—​—​​—​​—​​78​​—​​78
Net loss​—​​—​—​​—​—​​—​—​—​—​​—​​—​​—​​(37,124)​​(37,124)
Balance as of December 31, 2023​1,785,714​$956​17,589,380​$55,840​81,242,587​$193,290​—$—​1,576,854​$—​$4,645​$37​$(230,403)​$(225,721)
Repurchase of unvested restricted stock awards​—​​—​—​​—​—​​—​—​—​(21,172)​​—​​—​​—​​—​​—
Issuance of Series C convertible preferred stock, net of issuance costs of $619​—​​—​—​​—​—​​—​116,275,239​199,526​—​​—​​—​​—​​—​​—
Conversion of convertible preferred stock to common stock upon closing of initial public offering​(1,785,714)​​(956)​(17,589,380)​​(55,840)​(81,242,587)​​(193,290)​(116,275,239)​(199,526)​24,978,715​​2​​449,610​​—​​—​​449,612
Issuance of common stock from initial public offering, net of underwriting discounts, commissions and other issuance costs​—​​—​—​​—​—​​—​—​—​15,220,588​​2​​234,300​​—​​—​​234,302
Exercises of common stock options​​​​​​​​​​​​​​​​​​​​38,427​​—​​275​​—​​—​​275
Stock-based compensation expense​—​​—​—​​—​—​​—​—​—​—​​—​​10,821​​—​​—​​10,821
Unrealized gain on investments​—​​—​—​​—​—​​—​—​—​—​​—​​—​​31​​—​​31
Foreign currency translation adjustment​—​​—​—​​—​—​​—​—​—​—​​—​​—​​126​​—​​126
Net loss​—​​—​—​​—​—​​—​—​—​—​​—​​—​​—​​(156,988)​​(156,988)
Balance as of December 31, 2024​—​$—​—​$—​—​$—​—$—​41,793,412​$4​$699,651​$194​$(387,391)​$312,458
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.